Inclusion Criteria:

1. Subjects must have histological confirmation of AML by WHO criteria and be ineligible for treatment with a standard cytarabine and anthracycline induction regimen due to co-morbidity or other factors.
2. Subjects must have received no prior treatment for AML with the exception of hydroxyurea, allowed through the first cycle of study treatment. NOTE: Subject may have been treated for prior Myelodysplastic Syndrome (excluding hypomethylating agents).
3. Subjects must have an Eastern Cooperative Oncology Group (ECOG) Performance status of 0 to 2.
4. Subject must have adequate renal function as demonstrated by a calculated creatinine clearance ≥ 50 mL/min; determined via urine collection for 24-hour creatinine clearance or by the Cockcroft Gault formula.
5. Subject must have adequate liver function.

Exclusion Criteria:

1. Subject has received treatment with a hypomethylating agent and/or cytarabine for a pre-existing myeloid disorder.
2. Subject must not have favorable risk cytogenetics as categorized by the NCCN Guidelines Version 2, 2014 for Acute Myeloid Leukemia.
3. Subject has t(8;21), inv(16) or t(15;17) karyotype abnormalities.
4. Subject has acute promyelocytic leukemia (French-American-British Class M3 AML).
5. Subject has known active CNS involvement with AML.
6. Subject has received the following within 7 days prior to the initiation of study treatment:
   1. Potent CYP3A inducers such as rifampin, carbamazepine, phenytoin, and St. John's wort;
   2. Warfarin or requires the use of warfarin and its equivalent drugs, such as phenprocoumon; (due to potential drug-drug interactions that may potentially increase the exposure of warfarin and complications of anticoagulant effect).
   3. CYP3A inhibitors such as fluconazole, ketoconazole, and clarithromycin.
7. Subject has a history of other malignancies prior to study entry, with the exception of:
   1. Adequately treated in situ carcinoma of the cervix uteri or carcinoma in situ of breast;
   2. Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin;
   3. Previous malignancy confined and surgically resected (or treated with other modalities) with curative intent. 
8. Subject has a white blood cell count > 25 × 10^9/L. Note: Hydroxyurea is permitted to meet this criterion.
9. Subject is a candidate for a bone marrow or stem cell transplant within 12 weeks after study enrollment.